LETTER TO THE EDITOR

Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma

Umme Kolsum 1,2 *, Arjun Ravi 1,2, Paul Hitchen 2, Satyanarayana Maddi 1, Thomas Southworth 1 and Dave Singh 1,2

Abstract

Eosinophilic COPD appears to be a distinct patient subgroup with an increased corticosteroid response. Eosinophilic COPD has been labelled as part of the asthma COPD overlap syndrome (ACOS). We compared the clinical characteristics of eosinophilic COPD patients (without any clinical history of asthma) and COPD patients with a childhood history of asthma. COPD patients with asthma were characterised by more allergies and more exacerbations, but less eosinophilic inflammation. While terms such as “ACOS” are used to “lump” patients together, we report distinct differences between eosinophilic COPD and COPD patients with asthma, and propose that these groups should be split rather than lumped.

Keywords: Eosinophils, COPD, Asthma COPD overlap, ACOS

To the Editor:

Eosinophilic COPD appears to be a distinct patient subgroup with a corticosteroid treatment response [1, 2]. Furthermore, some, but not all, studies have shown that higher blood eosinophil counts in COPD patients predict a higher exacerbation rate in the future [3, 4]. The presence of eosinophilic inflammation in this COPD subgroup suggests that a similarity to asthma is present. Indeed, eosinophilic COPD has been labelled as part of the asthma-COPD overlap, also termed the asthma COPD overlap syndrome (ACOS) [5]. The asthma-COPD overlap consists of multiple subgroups of patients with distinct clinical and pathophysiological features, and there is a need to further define the characteristics of these subgroups [6]. We have compared the clinical characteristics of eosinophilic COPD patients without any clinical history of asthma, and COPD patients with a childhood history of asthma. The aim was to understand the similarities and differences between eosinophilic COPD and patients with a clinical diagnosis of both asthma and COPD.

Patients were recruited (Oct 2014-June 2016) from a research database of COPD patients from primary care who responded to media advertising. Two groups of patients were recruited: 67 COPD patients with no history of asthma were randomly selected from the database, and 14 COPD patients were specifically selected due to a history of childhood asthma (asthma and COPD; AC). 14 of the 67 COPD patients without asthma had a blood eosinophil count ≥300 cells/μl and were called COPD blood eosinophil high, while 24 patients had a sputum eosinophil count ≥3% and were called COPD sputum eosinophil high. All patients were aged >40 years, with post-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio <0.7 and ≥10 pack year smoking history. COPD patients attended for a visit at stable state; defined as not experiencing an exacerbation requiring antibiotics and/or oral corticosteroids in the preceding 6 weeks. Exacerbation history in the 12 months prior to study entry was based on patient recall. All patients provided written informed consent using protocols approved by the Greater Manchester Ethics Committees (10/H/1003/108 and 05/Q1402/41). COPD patients performed the following procedures: St George’s Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT),...
Clinical COPD Questionnaire (CCQ), skin prick testing, fat free mass index (FFMI) assessment, FeNO50 measurements, spirometry, body plethysmography, transfer factor, 6 minute walk test (6MWT), and sputum induction as previously described [7]. Sputum was processed for differential cell counts and quantitative polymerase chain reaction detection of *H.influenzae*, *M.catarrhalis* and *S.pneumoniae* as previously described [8]. Blood eosinophil counts and serum immunoglobulin E (IgE) levels (upper limit of normal = 100 IU/ml) were measured. A sample size of approximately 15 patients with AC and eosinophil^high^ COPD was planned, giving 80% power to detect a difference in sputum eosinophil % of 3.8% between groups using a SD of 3.6 based on our own and published data [9]. Statistical analyses were performed using unpaired t-tests, Mann-Whitney tests or chi-square tests as appropriate using GraphPad Prism version 7.00 (San Diego, California; USA). P < 0.05 was considered statistically significant.

The clinical characteristics are shown in Table 1. The AC group were significantly younger (means: 57 versus 69 years; *p* < 0.0001) with an earlier age of diagnosis compared to the COPD group, although the duration of COPD after diagnosis was similar between groups. Pack year history and inhaled corticosteroid use were similar between groups. More AC patients reported chronic bronchitis compared to COPD patients (86% versus 55%, *p* = 0.04), while CAT, SGRQ and CCQ scores were similar between groups. These demographic and symptomatic differences between groups were also present when comparing the AC and both the blood and sputum eosinophil^high^ COPD patients, except for chronic bronchitis prevalence which was no longer different between groups. AC patients experienced more exacerbations in the previous year (median = 3) compared to the whole COPD population, or the blood and sputum eosinophil^high^ COPD subgroups (median = 1 for all groups).

Focusing on the comparison of AC and blood eosinophil^high^COPD patients, the self-reported prevalence of allergies, including hayfever, and the presence of positive skin prick tests were higher in the AC group, although the total IgE count was similar between groups. The post-bronchodilator FEV1 % predicted was not different between groups, but the FEV1/FVC ratio was higher in the AC group (mean: 0.52 vs. 0.42, *p* = 0.02). There were no differences between groups for other pulmonary function tests including lung volumes and reversibility, 6MWD or FeNO50.

Blood eosinophil counts were higher in the blood eosinophil^high^ COPD patients; only 35.7% of AC patients had blood eosinophil counts ≥300 cells/μL (*p* = 0.0006), and median eosinophil counts were lower in AC patients (medians: 0.42×10^9^/L vs. 0.22×10^9^/L, *p* = 0.001). Sputum eosinophil counts, both as a percentage (median: 7.0 vs. 2.5, *p* = 0.002) and absolute count (median: 0.4 vs. 0.1, *p* < 0.01), were higher in blood eosinophil^high^ COPD compared to the AC patients respectively. Additionally, all patients in the blood eosinophil^high^ group had sputum eosinophil counts ≥3% (100%) compared to the AC group (46.2%), *p* = 0.008. There were no other differences between groups for sputum cell counts. Patients from each group were classified according to sputum cell counts into neutrophilic, eosinophilic, mixed granulocytic and pauci-granulocytic using neutrophil and eosinophil thresholds of 61% and 3% respectively as previously described [10]. The COPD blood eosinophil^high^ patients were classified as either eosinophilic (30%) or mixed (70%), AC patients had a more even spread between the four possible groups (Table 1). Total airway bacterial load was similar between the groups.

Comparison of sputum eosinophil^high^ COPD and AC patients (Table 2) showed similar findings to those observed between blood eosinophil^high^ COPD and AC patients; there was a higher prevalence of allergy in AC patients. In addition, AC patients had a significantly higher pre- and post-bronchodilator FEV1 L, FEV1 % predicted and FEV1/FVC ratios compared to sputum eosinophil^high^ COPD patients. Sputum eosinophil % (medians: 6.0 versus 2.5, *p* = 0.0004) and absolute counts (medians: 0.1×10^6^/g versus 0.04 ×10^6^/g) were higher in sputum eosinophil^high^ COPD patients compared to AC patients respectively, with only 46.2% of AC patients having a sputum eosinophil count ≥3% (*p* = 0.0002). There were no differences in blood eosinophil counts between the two groups.

We observed that AC patients are younger with more allergic symptoms, but less evidence of eosinophilic inflammation compared to both blood and sputum eosinophil^high^ COPD patients. These differences were associated with a higher rate of exacerbations in AC patients. While terms such as “ACOS” may be used to “lump” patients together, we report distinct differences between eosinophilic COPD and AC patients, and propose that these groups should be split rather than lumped.

The most notable clinical difference between AC patients and both the blood and sputum eosinophil^high^ COPD patients was the exacerbation rate. Similar findings have previously been reported comparing ACOS and COPD patients [11, 12]. The higher exacerbation rate may be linked to allergic mechanisms in AC patients that are not present in eosinophil^high^ COPD patients. The degree of eosinophilic airway inflammation was lower in AC patients compared to both the blood and sputum eosinophil^high^ COPD patients. The different nature of airway inflammation in these two groups further underscores that these are distinct subgroups that should not be lumped.

Interestingly, AC patients had less severe airflow obstruction measured by FEV1/FVC ratio; this is difficult to explain given the similar smoking histories of the
Table 1 Differences and similarities in clinical features between the COPD population, blood eosinophil\textsuperscript{high} COPD subgroup and AC patients

|                      | AC n = 14 | COPD population n = 67 | Blood Eosinophil\textsuperscript{high} COPD subgroup n = 14 | A vs. B p value | A vs. C p value |
|----------------------|-----------|------------------------|--------------------------|----------------|----------------|
| Gender (% Male)      | 79        | 67                     | 79                       | 0.53           | >0.99          |
| Age (years)          | 57.0 (6.9) | 69.2 (6.7)             | 66.7 (8.3)               | <0.0001        | 0.002          |
| BMI (kg/m\textsuperscript{2}) | 29.1 (4.5) | 27.0 (5.3)             | 27.8 (4.9)               | 0.18           | 0.47           |
| FFMI (kg/m\textsuperscript{2}) | 16.8 (2.7) | 16.8 (4.4)             | 17.3 (3.3)               | 0.98           | 0.69           |
| Smoking history (% Ex) | 71        | 78                     | 79                       | 0.73           | >0.99          |
| Pack years           | 33.7 [13.5–69.8] | 44.0 [14.5–154.0]     | 47.1 [24.0–154.0]        | 0.25           | 0.09           |
| Exacerbation (12mths prior) | 3 [0–5] | 1 [0–6]                | 1 [0–4]                 | 0.003          | 0.04           |
| Chronic bronchitis (%) | 86        | 55                     | 64                       | 0.04           | 0.38           |
| Any comorbidities (%) | 85        | 84                     | 79                       | >0.99          | >0.99          |
| Age COPD diagnosis   | 50.7 (5.9) | 61.2 (7.5)             | 61.7 (7.5)               | <0.0001        | 0.0002         |
| Duration of COPD diagnosis (years) | 8 [0.5–16] | 8 [1–38]               | 7.5 [3–11]              | 0.52           | 0.94           |
| ICS use (%)          | 93        | 78                     | 71                       | 0.28           | 0.33           |
| ICS dose (BDP equivalent) | 1550 [0–2000] | 1000 [0–2000]        | 900 [0–2000]             | 0.45           | 0.35           |
| SGRQ total           | 34.0 [15.3–78.8] | 46.7 [3.2–90.5]      | 39.1 [3.2–90.5]         | 0.95           | 0.65           |
| CAT                  | 19.3 (8.8) | 17.7 (8.5)             | 16.4 (10.1)              | 0.53           | 0.37           |
| CCQ total            | 1.8 [0.6–5.1] | 2.2 [0.1–4.8]        | 1.8 [0.1–4.1]            | 0.88           | 0.53           |
| Skin prick positive to >1 allergen (%) | 50       | 1.54                   | 7.14                     | <0.0001        | 0.03           |
| Allergic rhinitis (%) | 0         | 4.6                    | 7.1                      | >0.99          | >0.99          |
| Hayfever (%)         | 57.1      | 10.4                   | 7.1                      | 0.0003         | 0.01           |
| Eczema (%)           | 35.7      | 11.9                   | 21.4                     | 0.04           | 0.68           |
| Yes to do you suffer from allergies (%) | 85.7  | 9.0                    | 7.1                      | <0.0001        | <0.0001        |
| Family history of asthma (%) | 53.8 | 23.4                   | 28.6                     | 0.04           | 0.44           |
| Total IgE (IU/ml)    | 156 [2–2458] | 51 [2–6360]          | 85 [8–307]               | 0.17           | 0.43           |
| High IgE (>100 IU/ml) | 50.0      | 37.3                   | 50.0                     | 0.23           | >0.99          |
| Pre FEV\textsubscript{1} (L) | 1.8 (0.7) | 1.3 (0.5)              | 1.4 (0.6)                | 0.005          | 0.21           |
| Pre FEV\textsubscript{1} (%) | 55.3 (16.6) | 49.0 (18.8)             | 51.8 (22.6)              | 0.25           | 0.64           |
| Pre FEV\textsubscript{1}/FVC | 0.5 (0.1) | 0.4 (0.1)              | 0.4 (0.2)                | 0.009          | 0.10           |
| Post FEV\textsubscript{1} (L) | 2.0 (0.7) | 1.4 (0.6)              | 1.6 (0.7)                | 0.003          | 0.20           |
| Post FEV\textsubscript{1} (%) | 61.5 (16.5) | 54.4 (18.9)             | 57.6 (22.8)              | 0.19           | 0.60           |
| Post FEV\textsubscript{1}/FVC | 0.52 (0.1) | 0.43 (0.1)              | 0.42 (0.1)               | <0.01          | 0.02           |
| Reversibility %      | 8.1 [4.9–30.4] | 9.0 [7.6–48.2]     | 11.2 [30.0–48.2]         | 0.96           | 0.67           |
| Reversibility (ml)   | 175.0 [100.0–510.0] | 100 [100–500]    | 130.0 [60.0–500.0]       | 0.37           | 0.90           |
| BDR ≥12% and 200ml (%) | 28.6    | 22.4                   | 35.7                     | 0.73           | >0.99          |
| BDR ≥15% and 400ml (%) | 14.3    | 4.5                    | 7.14                     | 0.20           | >0.99          |
| Raw (kPa.sec)        | 0.4 (0.2) | 0.4 (0.2)              | 0.6 (0.4)                | 0.91           | 0.31           |
| sGaw (kPa.sec)       | 0.4 [0.2–1.1] | 0.5 [0.1–2.9]         | 0.4 [0.1–1.3]            | 0.91           | 0.66           |
| VC %                 | 89.8 [77.9–111.5] | 89.2 [59.8–141.5]    | 91.8 [65.8–141.5]        | 0.88           | >0.99          |
| TLC%                 | 106.9 (16.4) | 107.8 (15.7)             | 110.5 (13.0)             | 0.85           | 0.59           |
| RV %                 | 145.3 (51.7) | 141.9 (51.2)             | 148.0 (46.9)             | 0.83           | 0.90           |
| IC %                 | 82.1 (14.0) | 72.8 (18.1)             | 68.9 (21.6)              | 0.09           | 0.10           |
patients. A contributing factor may be the age difference between the groups, as the FEV₁/FVC ratio is known to decrease with age [13]. The younger age of the AC patients has been noted in other studies of the asthma COPD overlap [12, 14], and may represent a tendency to diagnose COPD earlier in patients with previous asthma.

Bronchodilator reversibility was similar between the AC and both the blood and sputum eosinophil high COPD groups. There was also no difference between AC and the whole COPD population; these findings agree with previous studies comparing bronchodilator reversibility in ACOS and COPD patients [15, 16]. Bronchodilator reversibility has been proposed as a distinguishing ACOS feature, but it is well known that COPD patients can display marked bronchodilator reversibility [17].

The sample size of this study was relatively limited for the AC and eosinophil high COPD groups, and therefore we may have missed some important differences between groups due to insufficient statistical power. However, by studying subgroups of COPD, we have reduced inter-patient variability for some endpoints, such as eosinophil counts, for which we were able to demonstrate large differences between groups. The small sample size prevented us from performing more complex statistical analysis, but nevertheless provides an initial insight into the differences between these patient groups.

The prevalence of eosinophil high COPD using a blood eosinophil count ≥300 cells/μl was 21%, while using a sputum eosinophil threshold of 3% gave a prevalence of 36%. Similarly, Watz et al [18], in a post hoc analysis of

---

**Table 1** Differences and similarities in clinical features between the COPD population, blood eosinophil high COPD subgroup and AC patients (Continued)

| Feature                          | ACOS | COPD | Blood eosinophil high COPD | BF | P value |
|----------------------------------|------|------|---------------------------|----|---------|
| FRC %                            | 125.5 (26.5) | 131.5 (39.8) | 142.1 (30.4) | 0.60 | 0.19    |
| KCO %                            | 79.2 (13.3)  | 76.5 (20.5)  | 81.9 (21.8)  | 0.65 | 0.69    |
| 6MWD (metres)                    | 376.4 (73.8) | 363.9 (104.6) | 399.1 (140.8) | 0.70 | 0.63    |
| FeNO 50 (ppb)                    | 11.3 [5.2–56.0] | 14.2 [3.8–42.6] | 16.6 [10.2–42.6] | 0.18 | 0.14    |
| Blood eosinophil count (10⁹/L)   | 0.20 [0.0–0.53] | 0.20 [0.02–1.14] | 0.42 [0.31–1.14] | 0.25 | 0.001   |
| Blood eosinophil %               | 3.5 [0.9–7.8]  | 2.8 [0.3–20.7]  | 5.4 [3.7–20.7]  | 0.10 | 0.002   |
| Blood eosinophil count ≥300 cells/μl | 35.7 | 20.9 | 100 | 0.30 | 0.0006 |
| Blood eosinophil >5%             | 14.3 | 13.4 | 64.3 | >0.99 | 0.02 |
| Sputum total cell count ×10⁶/g   | 3.3 [1.0–21.2] | 5.9 [0.5–116.0] | 6.2 [0.7–24.1] | <0.01 | 0.17 |
| Sputum neutrophil %              | 68.8 [27.5–91.0] | 82.8 [33.3–99.8] | 74.8 [48.0–90.6] | 0.02 | 0.53   |
| Sputum macrophage %              | 21.2 [6.8–44.0] | 11.6 [0.3–58.8] | 18.1 [1.24–31.5] | 0.02 | 0.23 |
| Sputum eosinophil %              | 2.5 [0.5–9.3]  | 2.6 [0.1–63.6]  | 7.0 [3.5–15.8]  | 0.92 | 0.002   |
| Sputum lymphocyte %              | 0.3 [0.0–4.5]  | 0.3 [0.0–5.0]  | 0.1 [0.0–1.0]  | 0.22 | 0.30   |
| Sputum epithelial cells %        | 2.8 [0.3–27.5] | 0.9 [0.0–13.0] | 2.1 [0.0–13.0] | 0.02 | 0.30   |
| Sputum neutrophil cell count ×10⁶/g | 2.5 [0.3–17.5] | 4.7 [0.3–112.5] | 4.6 [0.4–21.8] | 0.01 | 0.15 |
| Sputum macrophage cell count ×10⁶/g | 0.6 [0.2–2.1] | 0.8 [0.0–5.3] | 0.58 [0.23–1.74] | 0.76 | 0.78 |
| Sputum eosinophil cell count ×10⁶/g | 0.1 [0.01–1.3] | 0.1 [0.0–1.3] | 0.4 [0.1–1.3] | 0.30 | <0.01 |
| Sputum lymphocyte cell count ×10⁶/g | 0.01 [0.0–0.06] | 0.0 [0.0–0.48] | 0.0 [0.0–0.08] | 0.98 | 0.82 |
| Sputum epithelial cell count ×10⁶/g | 0.15 [0.01–0.92] | 0.05 [0.0–1.35] | 0.07 [0.0–0.89] | 0.03 | 0.34 |
| Sputum eosinophil ≥3%b   | 46.2 | 36 | 100 | >0.99 | 0.008 |
| Eosinophilic/Mixed/Neutrophilic/ Paucigranulocytic (%) | 8/33| 31/23 | 8/40| 46/6 | 30/70| 0/0 | <0.0001   | <0.0001 |
| Bacterial load (genome copies/ml) | 4.97×10⁶ [0.00–2.06×10⁶] | 7.55×10⁶ [0.00–4.01×10⁶] | 5.52×10⁶ [0.00–9.33×10⁶] | 0.41 | 0.77 |
| Colonised (sum bacterial load ≥1×10⁴) (%) | 83 | 65 | 64 | 0.31 | 0.37 |

Data is presented as mean (SD), medians [range] or % as appropriate; spirometry values were related to the reference values of the European Community for Coal and Steel (ECSS). The bold *p* values represent significant *p* values

*14 out of the 67 COPD patients (Group B) with no history of asthma had blood eosinophil count ≥300 cells/μl (Eosinophil high, Group C)

*50 patients from the COPD population produced a sputum sample

Definitions of abbreviations: AC COPD with childhood asthma diagnosis, ICS Inhaled corticosteroids, BDP Beclometasone disproportionate, BMI Body Mass Index, FFR Fat Free Mass Index, BDR Bronchodilator response, Raw Airway resistance, SGRQ St George’s Respiratory Questionnaire, CCQ Clinical COPD Questionnaire, CAT COPD Assessment Test, Pre Pre bronchodilator, Post Post bronchodilator, FEV1 Forced Expiratory Volume in first second, FVC Forced vital capacity, VC Vital Capacity, TLC Total Lung Capacity, RV Residual Volume, IC Inspiratory Capacity, FRC Functional Residual Capacity, KCO Carbon monoxide transfer coefficient, 6MWD 6 minute walk distance, FeNO3 Fractional exhaled nitric oxide at 50ml/sec flow rate.
Table 2 Differences and similarities in clinical features between sputum eosinophil<sup>high</sup> and AC patients

|                          | AC \(n = 14\) | Sputum Eosinophil<sup>high</sup> subgroup \(n = 24\) | \(p\) value |
|--------------------------|---------------|---------------------------------------------|-------------|
| Gender (% Male)          | 79            | 75                                          | >0.99       |
| Age (years)              | 57.0 (6.9)    | 68.3 (7.9)                                  | <0.0001     |
| BMI (kg/m<sup>2</sup>)   | 29.1 (4.5)    | 27.1 (4.5)                                  | 0.19        |
| FFMI (kg/m<sup>2</sup>)  | 16.8 (2.7)    | 17.2 (3.7)                                  | 0.70        |
| Smoking history (% Ex)   | 71            | 58                                          | 0.51        |
| Pack years               | 33.7 [13.5–69.8] | 46.3 [16.8–154.0] | 0.06        |
| Exacerbation (12mths prior) | 3 [0–5]     | 1 [0–5]                                    | 0.02        |
| Chronic bronchitis (%)   | 86            | 71                                          | 0.44        |
| Any comorbidities (%)    | 85            | 79                                          | >0.99       |
| Age COPD diagnosis        | 50.7 (5.9)    | 62.7 (7.7)                                  | <0.0001     |
| Duration of COPD diagnosis (years) | 8 [0.5–16.0] | 5.5 [2.0–17.0] | 0.71        |
| ICS use (%)              | 93            | 79                                          | 0.38        |
| ICS dose (BDP equivalent) | 1550 [0–2000] | 1000 [0–2000]    | 0.60        |
| SGRQ total               | 34.0 [15.3–78.8] | 51.5 [6.0–90.5] | 0.34        |
| CAT                      | 19.3 (8.8)    | 18.9 (9.9)                                  | 0.90        |
| CCQ total                | 1.8 [0.6–5.1] | 2.5 [0.5–4.7]                               | 0.74        |
| Skin prick positive to >1 allergen (%) | 50      | 0                                           | 0.0003      |
| Allergic rhinitis (%)    | 0             | 8.7                                         | 0.52        |
| Hayfever (%)             | 57.1          | 12.5                                        | 0.0008      |
| Eczema (%)               | 35.7          | 25.0                                        | 0.71        |
| Yes to do you suffer from allergies? (%) | 85.7       | 8.3                                         | <0.0001     |
| Family history of asthma (%) | 53.8       | 36.4                                        | 0.48        |
| Total IgE (IU/ml)        | 156 [2–2458]  | 69.5 [2–1868]                               | 0.30        |
| High IgE (>100 IU/ml)    | 50.0          | 71.4                                        | 0.74        |
| Pre FEV<sub>1</sub> (L)  | 1.8 (0.7)     | 1.2 (0.4)                                   | 0.003       |
| Pre FEV<sub>1</sub> (%)  | 55.3 (16.6)   | 44.8 (14.4)                                 | 0.048       |
| Pre FEV<sub>1</sub>/FVC  | 0.5 (0.1)     | 0.3 (0.1)                                   | <0.001      |
| Post FEV<sub>1</sub> (L) | 2.0 (0.7)     | 1.3 (0.4)                                   | 0.003       |
| Post FEV<sub>1</sub> (%) | 61.5 (16.5)   | 51.0 (14.1)                                 | 0.04        |
| Post FEV<sub>1</sub>/FVC | 0.5 (0.1)     | 0.4 (0.1)                                   | <0.001      |
| Reversibility %          | 8.1 [4.9–30.4] | 15.7 [0–48.2]   | 0.15        |
| Reversibility (ml)       | 175.0 [-100.0–510.0] | 125.0 [-60.0–400.0] | 0.87         |
| BDR ≥12% and 200ml (%)   | 28.6          | 37.5                                        | 0.73        |
| BDR ≥15% and 400ml (%)   | 14.3          | 4.2                                         | 0.54        |
| Raw (kPa.sec)            | 0.4 (0.2)     | 0.6 (0.2)                                   | 0.11        |
| sGaw (kPa.sec)           | 0.4 [0.2–1.1] | 0.4 [0.1–1.2]                               | 0.30        |
| VC %                     | 89.8 [77.9–111.5] | 88.9 [65.8–129.5] | 0.60        |
| TLC%                     | 106.9 (16.4)  | 112.3 (17.0)                                | 0.38        |
| RV %                     | 145.3 (51.7)  | 151.1 (64.5)                                | 0.79        |
| IC %                     | 82.1 (14.0)   | 67.4 (12.3)                                 | 0.004       |
| FRC %                    | 125.5 (26.5)  | 138.9 (48.5)                                | 0.37        |
| KCO %                    | 79.2 (13.3)   | 75.6 (19.8)                                 | 0.56        |
| 6MWD (metres)            | 376.4 (73.8)  | 330.4 (95.1)                                | 0.16        |
The datasets supporting the conclusions of this article are included within the article.

Abbreviations

6MWT: 6 minute walk test; ACOS: Asthma COPD overlap syndrome; CAT: COPD assessment test; CCQ: Clinical COPD Questionnaire; COPD: Chronic obstructive pulmonary disease; FeNO 50 (ppb): Fractional exhaled nitric oxide at 50ml/sec flow rate; FEV1: Forced expiratory volume in 1 second; FVC: Forced vital capacity; ICS: Inhaled corticosteroids; FRC: Functional Residual Capacity; ICR: Inhaled corticosteroids; IGES: Immunoglobulin E; SGRQ-C: St George's respiratory questionnaire

Acknowledgments

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

In conclusion, our findings demonstrate that eosinophilic COPD patients have distinct characteristics compared to COPD patients with a history of asthma. AC patients are characterised by the presence of allergies and more exacerbations, but less evidence of eosinophilic inflammation. These data support the concept that different subgroups exist within the asthma COPD overlap, and should be carefully characterised [6].
Authors’ contributions
UK and DS were responsible for the concept and design of study. UK, AR, PH and SM were involved in data acquisition. UK and DS was responsible for data analysis, interpretation and drafting the manuscript. AR, PH, SM, and TS revised the manuscript critically for intellectual content. All authors have approved the final version to be published and are jointly accountable for all aspects of the work.

Competing interests
UK, AR, PH, SM, TS declare that they have no competing interests; DS has received has received grant support, honoraria for lecturing and has consulting agreements from various pharmaceutical companies including Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Genentech, GlaxoSmithKline, Glenmark, Merck, NAPP, Novartis, Pfizer, Skypharma, Takeda, Teva, Theravance and Verona.

Consent for publication
Not Applicable.

Ethics approval and consent to participate
All patients provided written informed consent using protocols approved by the local Ethics Committees (Greater Manchester 10/H/1003/108 and 05/Q1402/41).

Published online: 26 April 2017

References
1. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60(3):193–8. doi:10.1136/thx.2004.032516. published Online First: Epub Date.
2. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523–5. doi:10.1164/rcrccm.201502-0235LE. published Online First: Epub Date.
3. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R. Eosinophilic inflammation in COPD; prevalence and clinical characteristics. Eur Respir J. 2014;44(4):1697–700. doi:10.1183/09031936.00162414. published Online First: Epub Date.
4. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and Exacerbations in COPD: the Copenhagen General Population Study. Am J Respir Crit Care Med. 2015. doi:10.1164/rccm.201509-1869OC. published Online First: Epub Date.
5. Barrecheguren M, Esquinas C, Miravitlles M. The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med. 2015;21(1):74–9. doi:10.1097/MCP.0000000000000118. published Online First: Epub Date.
6. Bateman ED, Reddel HK, van Zyl-Smit RN, Agusti A. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med. 2015;3(9):719–28. doi:10.1016/S2213-2600(15)00254-4. published Online First: Epub Date.
7. Ravi AK, Khurana S, Lemon J, et al. Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. Respir Res. 2014;15:103. doi:10.1186/s12931-014-0103-4. published Online First: Epub Date.
8. Garcia DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012;67(12):1075–80. doi:10.1136/thoraxjnl-2012-201924. published Online First: Epub Date.
9. Leigh R, Pizzichini MM, Morris MM, Maltas F, Hargave FE, Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2009;34(5):964–71. doi:10.1183/09031936.00072105. published Online First: Epub Date.
10. Ghentre MA, Bafadhel M, Desai D, et al. Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2015;135(1):63–72. doi:10.1016/j.jaci.2014.06.035. published Online First: Epub Date.
11. Menezes AM, Montes de Oca M, Perez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014;145(2):297–304. doi:10.1378/chest.13-0622. published Online First: Epub Date.
12. Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12:127. doi:10.1186/1465-9921-12-127. published Online First: Epub Date.
13. Medbo A, Melbye H. Lung function testing in the elderly--can we still use FEV1/FVC<70% as a criterion of COPD? Respir Med. 2007;101(6):1097–105. doi:10.1016/j.rmed.2006.11.019. published Online First: Epub Date.
14. Wurst NE, Rheault TR, Edwards L, Tal-Singer R, Agusti A, Vestbo J. A comparison of COPD patients with and without ACOS in the ECLIPSE study. Eur Respir J. 2016;47(5):1559–62. doi:10.1183/13993003.00245-2015. published Online First: Epub Date.
15. Hardin M, Cho M, McDonald ML, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J. 2014;44(2):341–50. doi:10.1183/09031936.00162414. published Online First: Epub Date.
16. Miravitlles M, Soriano JB, Ancochea J, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med. 2013;107(7):1053–60. doi:10.1016/j.rmed.2013.03.007. published Online First: Epub Date.
17. Calverley PM, Albert P, Walker PP. Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. Lancet Respir Med. 2013;1(7):564–73. doi:10.1016/S2213-2600(13)70086-9. published Online First: Epub Date.
18. Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–8. doi:10.1016/S2213-2600(16)00100-4. published Online First: Epub Date.
19. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1511–7. doi:10.1164/ajrccm.158.5.9804028. published Online First: Epub Date.